Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat.

Department of Physiology, Muscle Metabolism Laboratory, University of Arizona College of Medicine, Tucson, AZ 85721-0093, USA.
Metabolism: clinical and experimental (Impact Factor: 3.61). 11/2008; 57(10):1465-72. DOI: 10.1016/j.metabol.2008.05.018
Source: PubMed

ABSTRACT Oxidative stress and protein glycation can contribute to the development of insulin resistance and complications associated with type 2 diabetes mellitus. The antioxidant alpha-lipoic acid (ALA) reduces oxidative stress and the formation of advanced glycation end products (AGEs) and improves insulin sensitivity in skeletal muscle and liver. The AGE inhibitor pyridoxamine (PM) prevents irreversible protein glycation, thereby reducing various diabetic complications. The potential interactive effects of ALA and PM in the treatment of whole-body and skeletal muscle insulin resistance have not been investigated. Therefore, this study was designed to determine the effects of combined ALA and PM treatments on reducing muscle oxidative stress and ameliorating insulin resistance in prediabetic obese Zucker rats. Obese Zucker rats were assigned to either a control group or to a treatment group receiving daily injections of the R-(+)-enantiomer of ALA (R-ALA, 92 mg/kg) or PM (60 mg/kg), individually or in combination, for 6 weeks. The individual and combined treatments with R-ALA and PM were effective in significantly (P < .05) reducing plantaris muscle protein carbonyls (33%-40%) and urine-conjugated dienes (22%-38%), markers of oxidative stress. The R-ALA and PM in combination resulted in the largest reductions of fasting plasma glucose (23%), insulin (16%), and free fatty acids (24%) and of muscle triglycerides (45%) compared with alterations elicited by individual treatment with R-ALA or PM. Moreover, the combination of R-ALA and PM elicited the greatest enhancement of whole-body insulin sensitivity both in the fasted state and during an oral glucose tolerance test. Finally, combined R-ALA/PM treatments maintained the 44% enhancement of in vitro insulin-mediated glucose transport activity in soleus muscle of obese Zucker rats treated with R-ALA alone. Collectively, these results document a beneficial interaction of the antioxidant R-ALA and the AGE inhibitor PM in the treatment of whole-body and skeletal muscle insulin resistance in obese Zucker rats.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Due to the growing computation rates of intensive signal processing applications, using Multiprocessor System on Chip (MPSoC) becomes an incontrovertible solution to meet the functional requirements. Today, Electronic System Level (ESL) design is considered a vital premise to overcome the design complexity intrinsic in the heterogeneity of these devices. However, the development of tools at the system level is in the face of extremely challenging requirements such as the rapid system prototyping, the accurate performance estimation, and the reliable design space exploration (DSE).Focusing on the issue of ESL development tools, this paper describes an MPSoC environment design which targets the Multidimensional Intensive Signal Processing (MISP) application domain. Within this environment, we have defined first a generic execution model that supports any type of MPSoC. It can adapt to any parallel application and handle efficiently the scheduling and synchronizations at all the levels of granularity. Second, a new Virtual Processor (VP) based simulation technique is proposed for implementing the execution model. This proposal leverages the high-level specification of the system to provide a heterogeneous MPSoCs simulation without using an Instruction Set Simulator (ISS). VP-based simulation is implemented in SystemC at a timed transactional level allowing a good trade-off between high simulation speed and performance estimation accuracy. The usefulness and the effectiveness of our MPSoC environment is illustrated through two MISP applications executed on a typical MPSoC. Results show that our approach enables fast MPSoC virtual prototyping, data transfers and timing analysis, and reliable DSE for architectural optimizations.
    Microprocessors and Microsystems 05/2012; · 0.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction : Systemic and vascular inflammation are two risk factors for the development of diabetic nephropathy. In diabetic patients, serum systemic and vascular inflammatory factors have positive correlations with albuminuria. The present study was designed to investigate the effects of combined administration of lipoic acid and pyridoxine on the serum concentrations of these factors in patients with diabetic nephropathy. Materials and Methods : The study was a double-blind randomized clinical trial in which 38 patients with diabetic nephropathy (23 females and 15 males) were randomly assigned to either the supplement-taking or the placebo group. The patients in the supplement group received 800 mg lipoic acid and 80 mg pyridoxine daily for 12 weeks, while the placebo group received corresponding placebos. At baseline and the end of week 12, a urine sample and 10 ml blood was collected from each patient after a 12 to 14-hour fast and serum high sensitive C-reactive protein (hs-CRP), soluble intercellular adhesion molecule type 1 (sICAM-1), soluble vascular cell adhesion molecule type 1 (sVCAM-1), sE-selectin, Interleukine-6 (IL-6), glucose, percent of blood hemoglobin A1c and urinary albumin were measured. Results : In the present study, no significant differences were observed between the two groups in mean changes of hs-CRP, IL-6, sICAM-1, sVCAM-1, sE-selectin, glucose, percent of blood hemoglobin A1c. Mean urinary albumin concentration decreased significantly in the supplement-taking group at the end of week 12, compared to the baseline (P<0.05) and the reduction was significant in comparison with the placebo group (P<0.05). Conclusion : The results of the present study indicate that combined administration of lipoic acid and pyridoxine has no effect on serum systemic and vascular inflammatory factors, but it reduces urinary albumin concentration significantly. Therefore, combined administration of lipoic acid and pyridoxine may have an effective role in retarding the progression of diabetic nephropathy with a mechanism different from the effects of these supplements on inflammation.
    Iranian Journal of Endocrinology and Metabolism 01/2010; 12(2):99-110.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, has been implicated in preventing human pathologies, such as diabetes and cancer. However, the mechanisms underlying the beneficial effects of PLP are still unclear. Using Drosophila as a model system, we show that PLP deficiency, caused either by mutations in the pyridoxal kinase-coding gene (dPdxk) or by vitamin B6 antagonists, results in chromosome aberrations (CABs). The CAB frequency in PLP-depleted cells was strongly enhanced by sucrose, glucose or fructose treatments, and dPdxk mutant cells consistently displayed higher glucose contents than their wild type counterparts, an effect that is at least in part a consequence of an acquired insulin resistance. Together, our results indicate that a high intracellular level of glucose has a dramatic clastogenic effect if combined with PLP deficiency. This is likely due to an elevated level of Advanced Glycation End-products (AGE) formation. Treatment of dPdxk mutant cells with α-lipoic acid (ALA) lowered both AGE formation and CAB frequency, suggesting a possible AGE-CAB cause-effect relationship. The clastogenic effect of glucose in PLP-depleted cells is evolutionarily conserved. RNAi-mediated silencing of PDXK in human cells or treatments with PLP inhibitors resulted in chromosome breakage, which was potentiated by glucose and reduced by ALA. These results suggest that patients with concomitant hyperglycemia and vitamin B6 deficiency may suffer chromosome damage. This might impact cancer risk, as CABs are a well-known tumorigenic factor.
    PLoS Genetics 03/2014; 10(3):e1004199. · 8.17 Impact Factor


1 Download
Available from